Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 7/20 | 0.67 |
| ▸ | IGF1R | P08069 | 6/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 2/20 | 0.57 |
| ▸ | DRD1 | P21728 | 2/20 | 0.57 |
| ▸ | DRD4 | P21917 | 2/20 | 0.57 |
| ▸ | DRD5 | P21918 | 2/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | DRD3 | P35462 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 2/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29381000 | 1.00 | ALOX15 (0.67) | ALOX15IGF1RKDM4EMAPTADRA2A | |
| SCHEMBL6340368 | 0.93 | ALOX15 (0.68) | ALOX15IGF1RKDM4EMAPTADRA2A | |
| SCHEMBL925636 | 0.90 | IAPP (0.62) | ALOX15IGF1RKDM4EMAPTADRA2A | |
| SCHEMBL30986806 | 0.90 | IAPP (0.62) | ALOX15IGF1RKDM4EMAPTADRA2A | |
| Hydrochloric Acid SCHEMBL10340417 | 0.89 | IAPP (0.61) | ALOX15IGF1RKDM4EMAPTADRA2A | |
| SCHEMBL18788836 | 0.85 | IGF1R (0.67) | ALOX15IGF1RKDM4EMAPTMAPK1 | |
| SCHEMBL30983759 | 0.84 | IGF1R (0.46) | ALOX15IGF1RIAPPACHESGMS1 | |
| SCHEMBL2307446 | 0.81 | ALOX15 (1.00) | ALOX15IGF1RKDM4EMAPTADRA2A | |
| SCHEMBL107170 | 0.81 | ALOX15 (0.90) | ALOX15IGF1RKDM4EMAPTADRA2A | |
| Dopamine SCHEMBL2487031 | 0.81 | MAPT (0.62) | ALOX15KDM4EMAPTADRA2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | claimed |
| EP-0354568-A2 | Novel catechol derivatives | Japan Tobacco Inc. (JP) | 1990-02-14 | — | — | EP | claimed |
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | disclosed |
| CN-1089086-C | Luminandide medicine | MILLS RANDELL L (US) | 2002-08-14 | — | — | CN | disclosed |
| EP-0414730-B1 | Chemical Compounds and pharmaceutical compositions capable of releasing a drug | MILLS RANDELL L (US) | 1999-12-15 | — | — | EP | disclosed |
| US-5773592-A | COMPRISES A CHEMILUMINESCENT MOIETY, A PHOTOCHROMIC MOIETY AND A BIOLOGICALLY ACTIVE AGENT CAPABLE OF BEING RELEASED | MILLS RANDELL LEE (US) | 1998-06-30 | — | — | US | disclosed |
| US-5428163-A | Luminides; chemiluminescence; redox system, releasing free drug | MILLS RANDELL L (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0414730-A4 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | — | 1993-06-16 | — | — | EP | disclosed |
| EP-0414730-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | Mills, Randell L. (US) | 1991-03-06 | — | — | EP | disclosed |
| CN-1047075-A | Luminandide medicine | MILLS RANDELL L (US) | 1990-11-21 | — | — | CN | disclosed |
| WO-1989009833-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | MILLS RANDELL L (US) | 1989-10-19 | — | — | WO | disclosed |
| US-4448730-A | ANTITUMOR AGENTS | RIET BARTHOLOMEUS VAN T | 1984-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | ALOX15 30/4885IGF1R 3103/4885KDM4E 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.